Introduction

40
Tetanus prophylaxis is part of routine veterinary care for horses in the industrialised world, 41 but recommendations for best practice vary widely between countries. For example, the 42 AAEP guidelines recommend annual boosters after basic immunisation, but state that 43 protective titres may persist for longer [1] . In Sweden, the general recommendation for 44 practitioners is to give a tetanus vaccination booster once every 3 years, whereas in the UK it 45 is generally recommended to give the booster every 2 years. In New Zealand, tetanus vaccines 46 are registered for boosters at 5-year intervals after basic immunisation 47 (http://www.ivsonline.co.nz). The situation is similar in human practice, where the 48 recommended booster intervals after basic immunisation vary between countries. However, 49 all intervals are considerably longer than postulated for horses with at least 10-20 years 50 between boosters being the norm. 51 Horses are one of the more susceptible species to tetanus based on relative amount of toxin 52 per weight required to produce lethal disease [2] . This is coupled with the fact that horses 53 may often be exposed to environments containing spores of C. tetani, increasing the risk of 54 contamination of wounds. These factors warrant good prophylaxis, however, more evidence-55 based knowledge is needed on the duration of immunity. Previous studies have examined 56 long-term duration of titres [3] [4] [5] [6] [7] [8] [9] , and these consistently show that what is thought to be 57 protective titres (>0.01 IU/ml) are well maintained for several years, but the vaccines used in 58 these studies often contain adjuvants that are no longer in use such as water in oil emulsions, 59 and results may not be able to be extrapolated to vaccines currently available.
60
The aim of this 3-year longitudinal study was to determine the development and duration of 61 tetanus antibody titres after basic immunisation of horses, using a combined tetanus and 62 influenza vaccine 1 with ISCOM matrix.
Thirty-four privately owned horses were enrolled at the start of the study. Horses were 66 identified through convenience sampling; owners known to the researchers were approached 67 and offered to participate based on likely availability for follow-up for the length of the study 68 period. Horses were eligible if they were between 5 and 11 months of age, had not previously 
Results
119
Titres were obtained for 34 horses after the first vaccination but numbers declined 120 throughout the study for reasons unrelated to this project and 8 horses (24%) remained at 121 the end of the experimental study period (Table 1) . Titres for individual horses are provided 122 as supplementary material. Horses received their first vaccination (V1) at a median age of 7 123 months (IQR 6 to 8 months). Age at the start of the study was missing for one horse.
124
At the first serum sampling, 13 horses (38%) had antibody levels below the limit of detection 125 (<0,04 IU/ml). Horses with no detectable antibodies had a median age of 7.5 months (IQR 6 126 to 8 months), compared to horses with detectable antibody levels with a median age of 6 showing that 7/7 horses had tetanus IgG titres above 0.04 IU/ml for two years after complete 187 basic immunisation with Equilis Prequenza Te, indicating that yearly boosters are excessive.
188
The New Zealand recommendation of a 5-yearly booster interval may be based on a paper by 189 Liefman (1980) where the author recommends this booster interval in the discussion. 190 Unfortunately, enquiries to the pharmaceutical companies responsible for these products in 
